By Moaz Nasir
TWA
______
As a medical journalist, I had the privilege of attending the prestigious European Association for the Study of the Liver (EASL) International Liver Congress™ in Milan. The event was a showcase of the latest innovations and research in hepatology, offering a window into the future of liver disease treatment.
Among the many impressive presentations, Pliant Therapeutics stood out with its announcement of new findings in the treatment of liver fibrosis. The company’s dedication to developing novel therapeutics for fibrotic diseases has the potential to alter the current treatment paradigm significantly.
Precision BioSciences’ late-breaking poster presentation was another highlight, revealing promising preclinical safety data for its PBGENE-HBV clinical candidate. This development could mark a significant milestone in the ongoing battle against Hepatitis B.
Helio Genomics also captured the attention of attendees with its oral presentation of results from the CLiMB pivotal trial. The company’s AI-driven approach to diagnostics and test development for cancer detection is a clear indication of the innovative progress in medical technology.
The EASL Congress was more than just a conference; it was a gathering of minds dedicated to improving patient outcomes and advancing the field of hepatology. As I prepare to share these stories with my readers, I am reminded of the importance of such events in bringing cutting-edge research to the forefront of public awareness.
